Condition
Sarcoidosis, Cardiac
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Terminated1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07604220Not Yet Recruiting
Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)
NCT05351554Phase 2TerminatedPrimary
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
Showing all 2 trials